Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.53 -0.2%	$10.48	$4.93 ▼ $14.44	$818.57M	0.8	1.02 million shs	750,369 shs
PRAX Praxis Precision Medicines	$48.78 +5.2%	$48.82	$26.70 ▼ $91.83	$1.03B	2.62	567,697 shs	317,150 shs
RCUS Arcus Biosciences	$10.51 +0.3%	$9.25	$6.50 ▼ $18.98	$1.12B	0.89	809,959 shs	726,948 shs
SCPH scPharmaceuticals	$4.85 +6.1%	$4.59	$1.94 ▼ $6.28	$258.50M	0.4	332,399 shs	289,254 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-0.21%	-4.12%	-28.93%	+26.56%	+50.08%
PRAX Praxis Precision Medicines	+5.17%	+3.61%	-14.56%	+29.91%	-8.72%
RCUS Arcus Biosciences	+0.13%	+1.15%	+7.84%	+16.19%	-40.49%
SCPH scPharmaceuticals	+6.13%	+5.43%	-9.68%	+46.53%	-10.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.7652 of 5 stars	3.5	1.0	4.7	2.0	0.8	0.6
PRAX Praxis Precision Medicines	1.7061 of 5 stars	3.4	1.0	0.0	2.4	1.7	0.0
RCUS Arcus Biosciences	2.3996 of 5 stars	3.4	3.0	0.0	2.8	1.7	0.0
SCPH scPharmaceuticals	4.5422 of 5 stars	3.5	5.0	4.2	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.00	Buy	$44.00	361.70% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	76.05% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	101.19% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	188.66% Upside

Current Analyst Ratings Breakdown

Latest SCPH, PRAX, RCUS, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	120.10	N/A	N/A	$19.21 per share	2.54
RCUS Arcus Biosciences	$258M	4.34	N/A	N/A	$5.16 per share	2.04
SCPH scPharmaceuticals	$36.33M	7.12	N/A	N/A	($0.40) per share	-12.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A

Latest SCPH, PRAX, RCUS, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	8.93	8.93
PRAX Praxis Precision Medicines	N/A	6.31	6.31
RCUS Arcus Biosciences	0.18	4.50	4.50
SCPH scPharmaceuticals	3.86	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
PRAX Praxis Precision Medicines	67.84%
RCUS Arcus Biosciences	92.89%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
PRAX Praxis Precision Medicines	2.70%
RCUS Arcus Biosciences	9.60%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

SCPH, PRAX, RCUS, and AVXL Headlines

Recent News About These Companies

scPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in July

August 21 at 11:17 AM | marketbeat.com

scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111

August 14, 2025 | msn.com

scPharmaceuticals Q2 2025 Earnings Call Highlights Growth

August 14, 2025 | theglobeandmail.com

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

August 14, 2025 | globenewswire.com

scPharmaceuticals management to meet with Craig-Hallum

August 12, 2025 | msn.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Acquired by King Luther Capital Management Corp

August 12, 2025 | marketbeat.com

Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to "Hold"

August 10, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

August 9, 2025 | theglobeandmail.com

SCPH Revenue Up 99%

August 9, 2025 | aol.comA

ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025

August 9, 2025 | msn.com

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | globenewswire.com

Shareholders in scPharmaceuticals (NASDAQ:SCPH) are in the red if they invested five years ago

August 5, 2025 | uk.finance.yahoo.com

scPharmaceuticals (SCPH) to Release Earnings on Thursday

August 5, 2025 | marketbeat.com

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

July 31, 2025 | globenewswire.com

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

July 25, 2025 | zacks.com

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

June 12, 2025 | finance.yahoo.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, PRAX, RCUS, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.53 -0.02 (-0.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.61 +0.08 (+0.84%)

As of 08/22/2025 07:07 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Praxis Precision Medicines NASDAQ:PRAX

$48.78 +2.40 (+5.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$48.84 +0.05 (+0.11%)

As of 08/22/2025 05:39 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Arcus Biosciences NYSE:RCUS

$10.51 +0.03 (+0.28%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$10.60 +0.09 (+0.87%)

As of 08/22/2025 04:10 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

scPharmaceuticals NASDAQ:SCPH

$4.85 +0.28 (+6.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.85 0.00 (0.00%)

As of 08/22/2025 04:04 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time